Tracy L Hagemann Selected Research

Alexander Disease (Alexander's Disease)

1/2022	Alexander disease: models, mechanisms, and medicine.
11/2021	Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment.
3/2021	Pexidartinib treatment in Alexander disease model mice reduces macrophage numbers and increases glial fibrillary acidic protein levels, yet has minimal impact on other disease phenotypes.
1/2020	Type II Alexander disease caused by splicing errors and aberrant overexpression of an uncharacterized GFAP isoform.
1/2018	Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease.
1/2018	Tissue and cellular rigidity and mechanosensitive signaling activation in Alexander disease.
2/2016	An In Vivo Pharmacological Screen Identifies Cholinergic Signaling as a Therapeutic Target in Glial-Based Nervous System Disease.
11/2015	Nitric oxide mediates glial-induced neurodegeneration in Alexander disease.
11/2013	Deficits in adult neurogenesis, contextual fear conditioning, and spatial learning in a Gfap mutant mouse model of Alexander disease.
1/2013	GFAP expression as an indicator of disease severity in mouse models of Alexander disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tracy L Hagemann Research Topics

Disease

18	Alexander Disease (Alexander's Disease) 01/2022 - 08/2005
5	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2021 - 08/2005
2	Body Weight (Weight, Body) 03/2021 - 08/2012
2	Brain Diseases (Brain Disorder) 01/2018 - 08/2005
2	Nervous System Diseases (Neurological Disorders) 02/2016 - 08/2012
2	Gliosis 01/2012 - 10/2006
2	Seizures (Absence Seizure) 07/2009 - 10/2006
1	Intellectual Disability (Idiocy) 11/2013
1	Acute-Phase Reaction 08/2005

Drug/Important Bio-Agent (IBA)

11	Glial Fibrillary Acidic ProteinIBA 01/2022 - 10/2006
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2005
2	Antisense OligonucleotidesIBA 11/2021 - 01/2018
2	CytokinesIBA 03/2021 - 08/2005
2	Messenger RNA (mRNA)IBA 01/2020 - 01/2013
2	AntioxidantsIBA 08/2012 - 01/2012
2	Kainic Acid (Kainate)IBA 07/2009 - 10/2006
1	ChemokinesIBA 03/2021
1	pexidartinibIBA 03/2021
1	Protein Isoforms (Isoforms)IBA 01/2020
1	Biological ProductsIBA 01/2018
1	LaminsIBA 01/2018
1	Cholinergic ReceptorsIBA 02/2016
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 02/2016
1	Cholinergic Agents (Cholinergics)IBA 02/2016
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2015
1	Protein AggregatesIBA 11/2013
1	Indicators and Reagents (Reagents)IBA 01/2013
1	Glutathione (Reduced Glutathione)IBA 08/2012
1	Neuroprotective AgentsIBA 08/2012
1	Glutamate-Cysteine LigaseIBA 08/2012
1	Transcription Factors (Transcription Factor)IBA 01/2012
1	Glutamic Acid (Glutamate)FDA Link 04/2010
1	Crystallins (Crystallin)IBA 04/2009
1	Mutant Proteins (Protein, Mutant)IBA 08/2005
1	Complement System Proteins (Complement)IBA 08/2005
1	Cytokine Receptors (Cytokine Receptor)IBA 08/2005

Therapy/Procedure

1	Therapeutics 11/2021